688073 毕得医药
已收盘 12-31 15:00:01
资讯
新帖
简况
每周股票复盘：毕得医药（688073）股东减持计划时间届满及新减持计划披露
证券之星 · 02:49
每周股票复盘：毕得医药（688073）股东减持计划时间届满及新减持计划披露
毕得医药（688073）披露股东减持股份计划公告，12月30日股价下跌5.88%
中金财经 · 12-30 18:23
毕得医药（688073）披露股东减持股份计划公告，12月30日股价下跌5.88%
12月30日毕得医药跌5.88%，兴业医疗保健混合A基金重仓该股
证券之星 · 12-30 15:34
12月30日毕得医药跌5.88%，兴业医疗保健混合A基金重仓该股
毕得医药六位股东拟减持合计不超0.95%股份
中金财经 · 2025-12-30
毕得医药六位股东拟减持合计不超0.95%股份
每周股票复盘：毕得医药（688073）股东减持1.12%股份触及5%整数倍
证券之星 · 2025-12-28
每周股票复盘：毕得医药（688073）股东减持1.12%股份触及5%整数倍
毕得医药：12月24日高管戴岚减持股份合计3.46万股
证券之星 · 2025-12-24
毕得医药：12月24日高管戴岚减持股份合计3.46万股
毕得医药（688073）披露股东权益变动触及5%整数倍的提示性公告，12月22日股价上涨0.87%
证券之星 · 2025-12-22
毕得医药（688073）披露股东权益变动触及5%整数倍的提示性公告，12月22日股价上涨0.87%
12月22日毕得医药发布公告，股东减持48.28万股
证券之星 · 2025-12-22
12月22日毕得医药发布公告，股东减持48.28万股
12月19日毕得医药发生1笔大宗交易 成交金额519.75万元
中金财经 · 2025-12-19
12月19日毕得医药发生1笔大宗交易 成交金额519.75万元
12月18日毕得医药现3笔大宗交易 机构净买入204万元
证券之星 · 2025-12-18
12月18日毕得医药现3笔大宗交易 机构净买入204万元
毕得医药（688073）披露补选第二届董事会非独立董事议案结果，12月10日股价上涨0.98%
证券之星 · 2025-12-10
毕得医药（688073）披露补选第二届董事会非独立董事议案结果，12月10日股价上涨0.98%
毕得医药（688073）披露拟补选非独立董事，12月2日股价下跌4.7%
证券之星 · 2025-12-02
毕得医药（688073）披露拟补选非独立董事，12月2日股价下跌4.7%
11月28日毕得医药现2笔折价16.15%的大宗交易 合计成交1103.49万元
证券之星 · 2025-11-28
11月28日毕得医药现2笔折价16.15%的大宗交易 合计成交1103.49万元
毕得医药(688073.SH)总经理戴岚拟减持不超0.16%股份
智通财经 · 2025-11-25
毕得医药(688073.SH)总经理戴岚拟减持不超0.16%股份
毕得医药补选秦存亭为非独立董事
中金财经 · 2025-11-25
毕得医药补选秦存亭为非独立董事
毕得医药（688073）披露补选第二届董事会非独立董事议案，11月24日股价上涨3.63%
证券之星 · 2025-11-24
毕得医药（688073）披露补选第二届董事会非独立董事议案，11月24日股价上涨3.63%
每周股票复盘：毕得医药（688073）将召开2025年Q3业绩说明会
证券之星 · 2025-11-23
每周股票复盘：毕得医药（688073）将召开2025年Q3业绩说明会
11月20日毕得医药涨5.34%，兴业医疗保健混合A基金重仓该股
证券之星 · 2025-11-20
11月20日毕得医药涨5.34%，兴业医疗保健混合A基金重仓该股
毕得医药涨5.34%，开源证券二个月前给出“买入”评级
证券之星 · 2025-11-20
毕得医药涨5.34%，开源证券二个月前给出“买入”评级
毕得医药（688073）披露召开2025年第三季度业绩说明会，11月19日股价下跌0.65%
证券之星 · 2025-11-19
毕得医药（688073）披露召开2025年第三季度业绩说明会，11月19日股价下跌0.65%
加载更多
公司概况
公司名称：
上海毕得医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-10-11
主营业务：
上海毕得医药科技股份有限公司的主营业务是为新药研发机构提供专业、高效的药物分子砌块及科学试剂产品及服务。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块脂肪族类化合物、催化剂和配体、活性小分子化合物。
发行价格：
88.00
{"stockData":{"symbol":"688073","market":"SH","secType":"STK","nameCN":"毕得医药","latestPrice":61.05,"timestamp":1767164401000,"preClose":60.65,"halted":0,"volume":963079,"delay":0,"changeRate":0.0066,"floatShares":43234200,"shares":90882900,"eps":1.6869,"marketStatus":"已收盘","change":0.4,"latestTime":"12-31 15:00:01","open":60.65,"high":62.02,"low":60.38,"amount":59012500,"amplitude":0.027,"askPrice":61.1,"askSize":4,"bidPrice":61.05,"bidSize":0,"shortable":0,"etf":0,"ttmEps":1.6869,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":60.65,"symbolType":"stock_kcb","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":66.72,"lowLimit":54.59,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":90882948,"isCdr":false,"pbRate":2.77,"roa":"--","peRate":36.190646,"roe":"5.93%","epsLYR":1.32,"committee":-0.529412,"marketValue":5548000000,"turnoverRate":0.0223,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-01-05。","afterMarket":{"amount":0,"volume":0,"close":61.05,"buyVolume":0,"sellVolume":0,"time":1767166437558,"indexStatus":"已收盘 12-31 15:30:00","preClose":60.65},"floatMarketCap":2639000000},"requestUrl":"/m/hq/s/688073","defaultTab":"news","newsList":[{"id":"2600036512","title":"每周股票复盘：毕得医药（688073）股东减持计划时间届满及新减持计划披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036512","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036512?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:49","pubTimestamp":1767293347,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，毕得医药报收于65.38元，较上周的64.5元上涨1.36%。本周关注点公司公告汇总：股东减持计划时间届满，兰旦管理减持0.79%股份。减持期间，兰旦管理通过大宗交易减持720,461股，占总股本0.79%；欣曦管理减持301,925股，占总股本0.33%；吴波未实施减持。本次减持计划已实施完毕，未提前终止，实际减持情况与此前披露计划一致。本次减持计划不会导致公司控制权变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2595679699","title":"毕得医药（688073）披露股东减持股份计划公告，12月30日股价下跌5.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595679699","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595679699?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:23","pubTimestamp":1767090214,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，股东李怡静、陈俊、李黎、杜鹃、耿勇、蒋亚妹合计持有公司0.99%股份，拟通过集中竞价方式减持不超过公司总股本0.95%的股份。减持原因为资金需要，减持期间为2026年1月7日至2026年4月6日，减持价格将按市场价格确定。公告指出，本次减持计划不会导致公司控制权发生变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251230/31904040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2595629097","title":"12月30日毕得医药跌5.88%，兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595629097","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595629097?lang=zh_cn&edition=full","pubTime":"2025-12-30 15:34","pubTimestamp":1767080047,"startTime":"0","endTime":"0","summary":"证券之星消息，12月30日毕得医药跌5.88%创60日新低，收盘报60.65元，换手率4.02%，成交量1.74万手，成交额1.07亿元。重仓毕得医药的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。该公募基金现任基金经理为陈旭。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000020248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2595775458","title":"毕得医药六位股东拟减持合计不超0.95%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2595775458","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595775458?lang=zh_cn&edition=full","pubTime":"2025-12-30 08:58","pubTimestamp":1767056327,"startTime":"0","endTime":"0","summary":"中访网数据 上海毕得医药科技股份有限公司于2025年12月30日发布股东减持股份计划公告。公告显示，公司股东李怡静、陈俊、李黎、杜鹃、耿勇、蒋亚妹因自身流动性需求，计划自2026年1月7日起的3个月内，通过集中竞价交易方式减持其持有的公司股份。本次拟减持股份合计不超过公司总股本的0.95%，具体为：李怡静拟减持不超过0.31%，陈俊拟减持不超过0.10%，李黎拟减持不超过0.22%，杜鹃拟减持不超过0.18%，耿勇拟减持不超过0.11%，蒋亚妹拟减持不超过0.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251230/31902232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2594242221","title":"每周股票复盘：毕得医药（688073）股东减持1.12%股份触及5%整数倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2594242221","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594242221?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:20","pubTimestamp":1766866819,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，毕得医药报收于65.38元，较上周的64.5元上涨1.36%。股本股东变化：董事戴岚减持3.46万股，占公司总股本0.038%。公司公告汇总：本次权益变动后一致行动人合计持股比例降至10.00%，不触发强制要约收购义务。减持后，三人合计持股比例由11.12%降至10.00%，触及5%整数倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2593474815","title":"毕得医药：12月24日高管戴岚减持股份合计3.46万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593474815","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593474815?lang=zh_cn&edition=full","pubTime":"2025-12-24 20:02","pubTimestamp":1766577721,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月24日市场公开信息、上市公司公告及交易所披露数据整理，毕得医药最新董监高及相关人员股份变动情况：2025年12月24日公司董事戴岚共减持公司股份3.46万股，占公司总股本为0.038%。变动期间公司股价上涨0.42%，12月24日当日收盘报65.3元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400035422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2593435120","title":"毕得医药（688073）披露股东权益变动触及5%整数倍的提示性公告，12月22日股价上涨0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593435120","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593435120?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:52","pubTimestamp":1766415129,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，毕得医药报收于65.06元，较前一交易日上涨0.87%，最新总市值为59.13亿元。该股当日开盘65.01元，最高65.54元，最低64.1元，成交额达2394.87万元，换手率为0.85%。公司近日发布公告称，股东舟山兰旦企业管理合伙企业及其一致行动人吴波、舟山欣曦企业管理合伙企业于2025年11月13日至12月19日期间，通过大宗交易方式合计减持公司股份1,022,386股，占公司总股本的1.12%。本次权益变动后，一致行动人合计持股比例由11.12%减少至10.00%，触及5%整数倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200035584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2593828494","title":"12月22日毕得医药发布公告，股东减持48.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593828494","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593828494?lang=zh_cn&edition=full","pubTime":"2025-12-22 20:01","pubTimestamp":1766404906,"startTime":"0","endTime":"0","summary":"证券之星消息，12月22日毕得医药发布公告《毕得医药:简式权益变动报告书》，其股东舟山兰旦企业管理合伙企业(有限合伙)、舟山欣曦企业管理合伙企业(有限合伙)于2025年11月14日至2025年12月19日间合计减持48.28万股，占公司目前总股本的0.5312%，变动期间该股股价下跌14.51%，截止12月19日收盘报64.5元。股东增减持详情见下表：根据毕得医药2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200029301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2592165693","title":"12月19日毕得医药发生1笔大宗交易 成交金额519.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592165693","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592165693?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:47","pubTimestamp":1766141236,"startTime":"0","endTime":"0","summary":"证券之星消息，12月19日毕得医药发生大宗交易，交易数据如下：大宗交易成交价格60元，相对当日收盘价折价6.98%，成交8.66万股，成交金额519.75万元，买方营业部为中国银河证券股份有限公司金华证券营业部，卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。近三个月该股共发生14笔大宗交易，合计成交1.02万手，折价成交14笔。截至2025年12月19日收盘，毕得医药报收于64.5元，下跌0.29%，换手率1.91%，成交量8242.0手，成交额5363.04万元。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202512/19/20251219158798.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202512/19/20251219158798.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251219/31878231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2592974350","title":"12月18日毕得医药现3笔大宗交易 机构净买入204万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974350","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592974350?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:51","pubTimestamp":1766051498,"startTime":"0","endTime":"0","summary":"证券之星消息，12月18日毕得医药发生大宗交易，交易数据如下：近三个月该股共发生13笔大宗交易，合计成交9358.0手，折价成交13笔。该股近期无解禁股上市。截至2025年12月18日收盘，毕得医药报收于64.69元，下跌1.57%，换手率0.76%，成交量3281.0手，成交额2134.06万元。该股近半年内有股东持股变动，合计净减持53.96万股，股东增减持明细如下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家；过去90天内机构目标均价为91.0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800027315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2590533330","title":"毕得医药（688073）披露补选第二届董事会非独立董事议案结果，12月10日股价上涨0.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590533330","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590533330?lang=zh_cn&edition=full","pubTime":"2025-12-10 22:28","pubTimestamp":1765376881,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘，毕得医药报收于67.92元，较前一交易日上涨0.98%，最新总市值为61.73亿元。该股当日开盘67.72元，最高68.4元，最低66.88元，成交额达2426.28万元，换手率为0.83%。近日，北京国枫律师事务所发布关于上海毕得医药科技股份有限公司2025年第五次临时股东会的法律意见书。会议审议通过了补选第二届董事会非独立董事的议案，秦存亭当选为公司非独立董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000042240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2588051143","title":"毕得医药（688073）披露拟补选非独立董事，12月2日股价下跌4.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588051143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588051143?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:41","pubTimestamp":1764686462,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，毕得医药报收于66.07元，较前一交易日下跌4.7%，最新总市值为60.05亿元。该股当日开盘69.45元，最高69.99元，最低65.85元，成交额达6246.24万元，换手率为2.16%。公司近日发布公告称，上海毕得医药科技股份有限公司拟补选秦存亭为第二届董事会非独立董事。秦存亭现任公司合规高级经理，未直接持有公司股份，间接持有约48,103股，占总股本0.0529%。该议案已提交2025年第五次临时股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200040430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2586833907","title":"11月28日毕得医药现2笔折价16.15%的大宗交易 合计成交1103.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586833907","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586833907?lang=zh_cn&edition=full","pubTime":"2025-11-28 17:49","pubTimestamp":1764323378,"startTime":"0","endTime":"0","summary":"证券之星消息，11月28日毕得医药发生大宗交易，交易数据如下：近三个月该股共发生9笔大宗交易，合计成交7205.0手，折价成交9笔。该股近期无解禁股上市。截至2025年11月28日收盘，毕得医药报收于72.75元，上涨0.64%，换手率1.09%，成交量4706.0手，成交额3406.68万元。该股近半年内有股东持股变动，合计净减持53.96万股，股东增减持明细如下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家；过去90天内机构目标均价为91.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800026484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2586942612","title":"毕得医药(688073.SH)总经理戴岚拟减持不超0.16%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2586942612","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586942612?lang=zh_cn&edition=full","pubTime":"2025-11-25 17:48","pubTimestamp":1764064089,"startTime":"0","endTime":"0","summary":"智通财经APP讯，毕得医药(688073.SH)发布公告，因自身资金需要，公司控股股东、实际控制人兼公司董事长、总经理戴岚计划根据市场情况拟于减持计划披露之日起15个交易日后的3个月内通过集中竞价交易方式减持其通过二级市场集中竞价交易取得的公司股份，减持数量不超过14.88万股，即不超过公司总股本的0.16%。减持价格将按照减持实际实施时的市场价格确定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2586904412","title":"毕得医药补选秦存亭为非独立董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2586904412","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586904412?lang=zh_cn&edition=full","pubTime":"2025-11-25 09:20","pubTimestamp":1764033612,"startTime":"0","endTime":"0","summary":"中访网数据 上海毕得医药科技股份有限公司(证券代码：688073，证券简称：毕得医药)于2025年11月24日召开第二届董事会第二十七次会议，审议通过了《关于补选公司第二届董事会非独立董事的议案》。董事会同意提名秦存亭先生为公司第二届董事会非独立董事候选人。秦存亭先生现任公司合规高级经理，通过员工持股平台间接持有公司股份约48,103股，约占公司总股本的0.0529%。此次董事补选旨在保证公司董事会的规范运作，秦存亭先生的董事任期将自公司股东大会审议通过之日起，至第二届董事会任期届满之日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251125/31821119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2585498797","title":"毕得医药（688073）披露补选第二届董事会非独立董事议案，11月24日股价上涨3.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498797","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498797?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:40","pubTimestamp":1763995251,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，毕得医药报收于75.61元，较前一交易日上涨3.63%，最新总市值为68.72亿元。该股当日开盘72.87元，最高76.67元，最低71.71元，成交额达5136.63万元，换手率为1.6%。公司近日发布公告称，将于2025年12月10日召开2025年第五次临时股东会，会议将审议《关于补选公司第二届董事会非独立董事的议案》，拟选举秦存亭为公司第二届董事会非独立董事。相关议案已经董事会审议通过，公告披露时间为2025年11月25日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400036394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2585106674","title":"每周股票复盘：毕得医药（688073）将召开2025年Q3业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2585106674","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585106674?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:37","pubTimestamp":1763843829,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，毕得医药报收于72.96元，较上周的74.4元下跌1.94%。本周，毕得医药11月21日盘中最高价报76.72元。11月19日盘中最低价报71.06元。毕得医药当前最新总市值66.31亿元，在医疗服务板块市值排名27/50，在两市A股市值排名2576/5167。投资者可于2025年11月20日至11月26日16:00前通过上证路演中心或公司邮箱ir@bidepharmatech.com提问，公司在说明会上将对普遍关注的问题进行回应。说明会结束后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2584714183","title":"11月20日毕得医药涨5.34%，兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584714183","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584714183?lang=zh_cn&edition=full","pubTime":"2025-11-20 15:33","pubTimestamp":1763623994,"startTime":"0","endTime":"0","summary":"证券之星消息，11月20日毕得医药涨5.34%，收盘报76.14元，换手率2.35%，成交量1.02万手，成交额7627.39万元。重仓毕得医药的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家；过去90天内机构目标均价为91.0。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。该公募基金现任基金经理为陈旭。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000017691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2584318588","title":"毕得医药涨5.34%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2584318588","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584318588?lang=zh_cn&edition=full","pubTime":"2025-11-20 15:33","pubTimestamp":1763623983,"startTime":"0","endTime":"0","summary":"今日毕得医药（688073）涨5.34%，收盘报76.14元。2025年8月24日，开源证券研究员余汝意,聂媛媛发布了对毕得医药的研报《公司信息更新报告：2025H1业绩超预期增长，科学试剂业务表现亮眼》，该研报对毕得医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为79.61%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为华创证券的万梦蝶。毕得医药（688073）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000017685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","161027"],"gpt_icon":0},{"id":"2584474769","title":"毕得医药（688073）披露召开2025年第三季度业绩说明会，11月19日股价下跌0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584474769","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584474769?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:34","pubTimestamp":1763562864,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘，毕得医药报收于72.28元，较前一交易日下跌0.65%，最新总市值为65.69亿元。公司近日发布公告称，上海毕得医药科技股份有限公司将于2025年11月27日14:00-15:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果及财务状况。投资者可于2025年11月20日至11月26日16:00前通过上证路演中心或公司邮箱ir@bidepharmatech.com提问，公司在说明会上将对普遍关注的问题进行回应。说明会结束后可通过上证路演中心查看会议情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900040238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767328799789,"stockEarnings":[{"period":"1week","weight":-0.0651},{"period":"1month","weight":-0.1194},{"period":"3month","weight":-0.2062},{"period":"6month","weight":0.0941},{"period":"1year","weight":0.2661},{"period":"ytd","weight":0.2661}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海毕得医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"3493人(较上一季度减少7.64%)","perCapita":"12377股","listingDate":"2022-10-11","address":"上海市杨浦区翔殷路128号11号楼A座101室","registeredCapital":"9088万元","survey":" 上海毕得医药科技股份有限公司的主营业务是为新药研发机构提供专业、高效的药物分子砌块及科学试剂产品及服务。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块脂肪族类化合物、催化剂和配体、活性小分子化合物。","listedPrice":88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"毕得医药,688073,毕得医药股票,毕得医药股票老虎,毕得医药股票老虎国际,毕得医药行情,毕得医药股票行情,毕得医药股价,毕得医药股市,毕得医药股票价格,毕得医药股票交易,毕得医药股票购买,毕得医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}